403 related articles for article (PubMed ID: 33858123)
1. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ;
Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123
[TBL] [Abstract][Full Text] [Related]
2. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
Li J; Wang X; Chen J; Zhang H; Deng A
JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Kurdi A; Abutheraa N; Akil L; Godman B
Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.
Megaly M; Glogoza M
Scott Med J; 2020 Nov; 65(4):123-126. PubMed ID: 32807019
[TBL] [Abstract][Full Text] [Related]
6. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
7. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.
Yahyavi A; Hemmati N; Derakhshan P; Banivaheb B; Karimi Behnagh A; Tofighi R; TehraniYazdi A; Kabir A
Intern Emerg Med; 2021 Jun; 16(4):883-893. PubMed ID: 33085063
[TBL] [Abstract][Full Text] [Related]
9. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
Pirola CJ; Sookoian S
J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
[TBL] [Abstract][Full Text] [Related]
11. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
[TBL] [Abstract][Full Text] [Related]
12. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
13. [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study].
Georges JL; Cochet H; Roger G; Ben Jemaa H; Soltani J; Azowa JB; Mamou R; Gilles F; Saba J; Prevot A; Pasqualini M; Monguillon V; De Tournemire M; Bertrand A; Koukabi-Fradelizi M; Beressi JP; Livarek B
Ann Cardiol Angeiol (Paris); 2020 Nov; 69(5):247-254. PubMed ID: 33039120
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia.
Görmez S; Erel Kırışoğlu C; Ekicibaşı ME; Değirmencioğlu A; Paudel A; Akan G; Atalar F; Sarıgüzel N; Pamukçu B
Turk Kardiyol Dern Ars; 2021 Jun; 49(4):286-292. PubMed ID: 34106062
[TBL] [Abstract][Full Text] [Related]
15. Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
Georges JL; Gilles F; Cochet H; Bertrand A; De Tournemire M; Monguillon V; Pasqualini M; Prevot A; Roger G; Saba J; Soltani J; Koukabi-Fradelizi M; Beressi JP; Laureana C; Prost JF; Livarek B
PLoS One; 2020; 15(12):e0244349. PubMed ID: 33347477
[TBL] [Abstract][Full Text] [Related]
16. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
Xie Q; Tang S; Li Y
Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study.
Landolfo M; Maino A; Di Salvo E; Fiorini G; Peterlana D; Borghi C
Intern Emerg Med; 2022 Aug; 17(5):1335-1341. PubMed ID: 35064437
[TBL] [Abstract][Full Text] [Related]
18. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Dos Santos TM; Mazza L; Feldman A; D'Andréa Saba Arruda G; de Albuquerque DC; Camiletti AS; de Sousa AS; de Paula TC; Giusti KGD; Domiciano RAM; Noya-Rabelo MM; Hamilton AM; Loures VA; Dionísio RM; Furquim TAB; De Luca FA; Dos Santos Sousa ÍB; Bandeira BS; Zukowski CN; de Oliveira RGG; Ribeiro NB; de Moraes JL; Petriz JLF; Pimentel AM; Miranda JS; de Jesus Abufaiad BE; Gibson CM; Granger CB; Alexander JH; de Souza OF;
JAMA; 2021 Jan; 325(3):254-264. PubMed ID: 33464336
[TBL] [Abstract][Full Text] [Related]
19. Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives.
Felice C; Nardin C; Di Tanna GL; Grossi U; Bernardi E; Scaldaferri L; Romagnoli M; Tonon L; Cavasin P; Novello S; Scarpa R; Farnia A; De Menis E; Rigoli R; Cinetto F; Pauletto P; Agostini C; Rattazzi M
Am J Hypertens; 2020 Oct; 33(10):944-948. PubMed ID: 32511678
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
Kim JH; Baek YH; Lee H; Choe YJ; Shin HJ; Shin JY
Epidemiol Health; 2021; 43():e2021004. PubMed ID: 33445824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]